Synopsis
Synopsis
0
EU WC
0
KDMF
0
VMF
0
FDF
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. Cornutamine
2. Ergo Kranit
3. Ergo Sanol
4. Ergo-kranit
5. Ergodryl Mono
6. Ergomar
7. Ergostat
8. Ergotamine
9. Ergotamine Tartrate
10. Ergotamine Tartrate (2:1)
11. Ergotaminine
12. Gynergen
13. Lingraine
14. Mono, Ergodryl
15. Tartrate, Ergotamine
1. Ergotamine Tartrate
2. Ergotamine Bitartrate
3. 379-79-3
4. Schembl8045
5. Akos015897172
6. Ac-14836
Molecular Weight | 731.7 g/mol |
---|---|
Molecular Formula | C37H41N5O11 |
Hydrogen Bond Donor Count | 7 |
Hydrogen Bond Acceptor Count | 12 |
Rotatable Bond Count | 7 |
Exact Mass | 731.28025714 g/mol |
Monoisotopic Mass | 731.28025714 g/mol |
Topological Polar Surface Area | 233 Ų |
Heavy Atom Count | 53 |
Formal Charge | 0 |
Complexity | 1350 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 6 |
Undefined Atom Stereocenter Count | 2 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 2 |
1 of 2 | |
---|---|
Drug Name | Ergomar |
PubMed Health | Ergotamine Tartrate (By mouth) |
Drug Classes | Antimigraine |
Active Ingredient | Ergotamine tartrate |
Dosage Form | Tablet |
Route | Sublingual |
Strength | 2mg |
Market Status | Prescription |
Company | Rosedale Therapeutic |
2 of 2 | |
---|---|
Drug Name | Ergomar |
PubMed Health | Ergotamine Tartrate (By mouth) |
Drug Classes | Antimigraine |
Active Ingredient | Ergotamine tartrate |
Dosage Form | Tablet |
Route | Sublingual |
Strength | 2mg |
Market Status | Prescription |
Company | Rosedale Therapeutic |
Adrenergic alpha-1 Receptor Agonists
Compounds that bind to and activate ADRENERGIC ALPHA-1 RECEPTORS. (See all compounds classified as Adrenergic alpha-1 Receptor Agonists.)
Analgesics, Non-Narcotic
A subclass of analgesic agents that typically do not bind to OPIOID RECEPTORS and are not addictive. Many non-narcotic analgesics are offered as NONPRESCRIPTION DRUGS. (See all compounds classified as Analgesics, Non-Narcotic.)
Oxytocics
Drugs that stimulate contraction of the myometrium. They are used to induce LABOR, OBSTETRIC at term, to prevent or control postpartum or postabortion hemorrhage, and to assess fetal status in high risk pregnancies. They may also be used alone or with other drugs to induce abortions (ABORTIFACIENTS). Oxytocics used clinically include the neurohypophyseal hormone OXYTOCIN and certain prostaglandins and ergot alkaloids. (From AMA Drug Evaluations, 1994, p1157) (See all compounds classified as Oxytocics.)
Serotonin Receptor Agonists
Endogenous compounds and drugs that bind to and activate SEROTONIN RECEPTORS. Many serotonin receptor agonists are used as ANTIDEPRESSANTS; ANXIOLYTICS; and in the treatment of MIGRAINE DISORDERS. (See all compounds classified as Serotonin Receptor Agonists.)
Vasoconstrictor Agents
Drugs used to cause constriction of the blood vessels. (See all compounds classified as Vasoconstrictor Agents.)
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
DRUG PRODUCT COMPOSITIONS
Related Excipient Companies
Excipients by Applications
Market Place
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
A Ergotamine Tartrate manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Ergotamine Tartrate, including repackagers and relabelers. The FDA regulates Ergotamine Tartrate manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Ergotamine Tartrate API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Ergotamine Tartrate manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Ergotamine Tartrate supplier is an individual or a company that provides Ergotamine Tartrate active pharmaceutical ingredient (API) or Ergotamine Tartrate finished formulations upon request. The Ergotamine Tartrate suppliers may include Ergotamine Tartrate API manufacturers, exporters, distributors and traders.
click here to find a list of Ergotamine Tartrate suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Ergotamine Tartrate DMF (Drug Master File) is a document detailing the whole manufacturing process of Ergotamine Tartrate active pharmaceutical ingredient (API) in detail. Different forms of Ergotamine Tartrate DMFs exist exist since differing nations have different regulations, such as Ergotamine Tartrate USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Ergotamine Tartrate DMF submitted to regulatory agencies in the US is known as a USDMF. Ergotamine Tartrate USDMF includes data on Ergotamine Tartrate's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Ergotamine Tartrate USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Ergotamine Tartrate suppliers with USDMF on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The Ergotamine Tartrate Drug Master File in Japan (Ergotamine Tartrate JDMF) empowers Ergotamine Tartrate API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the Ergotamine Tartrate JDMF during the approval evaluation for pharmaceutical products. At the time of Ergotamine Tartrate JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of Ergotamine Tartrate suppliers with JDMF on PharmaCompass.
A Ergotamine Tartrate CEP of the European Pharmacopoeia monograph is often referred to as a Ergotamine Tartrate Certificate of Suitability (COS). The purpose of a Ergotamine Tartrate CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of Ergotamine Tartrate EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of Ergotamine Tartrate to their clients by showing that a Ergotamine Tartrate CEP has been issued for it. The manufacturer submits a Ergotamine Tartrate CEP (COS) as part of the market authorization procedure, and it takes on the role of a Ergotamine Tartrate CEP holder for the record. Additionally, the data presented in the Ergotamine Tartrate CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the Ergotamine Tartrate DMF.
A Ergotamine Tartrate CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. Ergotamine Tartrate CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of Ergotamine Tartrate suppliers with CEP (COS) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Ergotamine Tartrate as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Ergotamine Tartrate API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Ergotamine Tartrate as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Ergotamine Tartrate and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Ergotamine Tartrate NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Ergotamine Tartrate suppliers with NDC on PharmaCompass.
Ergotamine Tartrate Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Ergotamine Tartrate GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Ergotamine Tartrate GMP manufacturer or Ergotamine Tartrate GMP API supplier for your needs.
A Ergotamine Tartrate CoA (Certificate of Analysis) is a formal document that attests to Ergotamine Tartrate's compliance with Ergotamine Tartrate specifications and serves as a tool for batch-level quality control.
Ergotamine Tartrate CoA mostly includes findings from lab analyses of a specific batch. For each Ergotamine Tartrate CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Ergotamine Tartrate may be tested according to a variety of international standards, such as European Pharmacopoeia (Ergotamine Tartrate EP), Ergotamine Tartrate JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Ergotamine Tartrate USP).
LOOKING FOR A SUPPLIER?